20170, 703–421–5826, FAX 703–444–1737.

Registration: Preregistration is recommended on or before May 29, 2002. Onsite registration will be done on a space-available basis on both days of the workshop, beginning at 7:30 a.m. You may obtain registration forms and information about registration fees from HelmsBriscoe Resource One (see the *Contact* section of this document) or from Joseph Wilczek, Project Manager, at wilczek@cber.fda.gov. Mail or fax your registration information and registration fee to HelmsBriscoe Resource One by May 29, 2002.

If you need special accommodations due to a disability, please contact HelmsBriscoe Resource One at least 7 days in advance.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The public workshop transcript will also be available on the Internet at http://www.fda.gov/cber/minutes/workshop-min.htm.

SUPPLEMENTARY INFORMATION: FDA and PPTA are jointly cosponsoring a public workshop on comparability studies for human plasma-derived therapeutics. The workshop will discuss critical issues and approaches for establishing the comparability of human plasma derivatives for supporting changes in manufacturing processes, equipment, or facilities. On May 30, 2002, the workshop will address the three levels of comparability studies—physical/chemical characterization, preclinical studies, and clinical evaluations as they are related to manufacturing changes for a human plasma derivative, as well as information on reporting manufacturing changes, comparability protocols, and several case studies.

On May 31, 2002, the workshop will focus on issues related to comparing fractionation intermediates, a topic specific to the plasma derivative industry. FDA will present historical perspectives and current guidance on cooperative manufacturing arrangements. Industry will discuss the current status of the necessity for fractionation intermediates from sources outside of the company and the criteria for acceptance. The complexities involved in characterizing the source material, intermediates, and the drug products will be discussed. The public workshop agenda will be posted on the Internet at http://www.fda.gov/cber/whatsnew.htm.

Dated: April 29, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 02–11208 Filed 5–6–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committees: Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on June 21, 2002, from 8 a.m. to 4:30 p.m.

Location: Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Sandra Titus, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, or e-mail: Tituss@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area) code 12541. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committees will consider the safety and efficacy of new drug application (NDA) 21–229, proposing over-the-counter (OTC) use of PRILOSEC1 (omeprazole magnesium), AstraZeneca LP/Procter and Gamble, for the prevention of the symptoms of frequent heartburn. The sponsor proposes a 20 milligram dose to be taken for 14 days. The background material for this meeting will be posted one working day before the meeting under the Nonprescription Drugs Advisory Committee (NDAC) on the Dockets Management Branch Web site at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm. (Click on the year 2002 and scroll down to NDAC.)

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 12, 2002. Oral presentations from the public will be scheduled on June 21, 2002, between approximately 8:15 a.m. and 9:15 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 12, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Sandra Titus at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 29, 2002.

Linda A. Suydam,

Senior Associate Commissioner for Communications and Constituent Relations.

[FR Doc. 02–11205 Filed 5–6–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Fiscal Year 2002 Competitive Application Cycle for the Radiation Exposure Screening and Education Program 93.257

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Correction.

SUMMARY: In notice document FR Doc. 02–10634, in the issue of Tuesday, April 30, 2002, make the following correction:

On page 21257 in the third column, under section ''Funding Preferences,'' replace the first bullet (which reads